ProCE Banner Activity

Outcomes in R/R AML After First-line Treatment With Venetoclax Plus a Hypomethylating Agent

Slideset Download
Conference Coverage
In a retrospective study, older patients with R/R AML following first-line venetoclax plus a hypomethylating agent have poor OS outcomes.

Released: December 13, 2019

Expiration: December 11, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company